← Back
Data updated: Mar 29, 2026
IDORSIA
CardiovascularGastroenterologyNeurology
Pharma
IDORSIA is a pharmaceutical company focused on Cardiovascular, Gastroenterology, Neurology. Key products include QUVIVIQ.
2022
Since
2
Drugs
-
Trials
6
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
TRYVIO 2025-04-02
REMS
TRYVIO 2024-12-09
REMS
QUVIVIQ 2024-09-30
Efficacy
QUVIVIQ 2024-09-30
Labeling
QUVIVIQ 2024-09-30
Efficacy
TRYVIO 2024-08-07
REMS
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 76%
1 drugs Phase 3: 2 Phase 2: 1
Gastroenterology 10%
0 drugs Phase 1: 2
Neurology 10%
0 drugs Phase 2: 1
Respiratory 5%
0 drugs Phase 1: 1
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
GE HEALTHCARE specialty
Neurology, Cardiovascular, Respiratory
APOTHECON specialty
Cardiovascular, Gastroenterology, Respiratory
LEDERLE big-pharma
Cardiovascular, Neurology, Respiratory
Novartis big-pharma
Cardiovascular, Respiratory
VALIDUS PHARMS specialty
Cardiovascular, Gastroenterology, Neurology